Saxon Interests’s Moderna MRNA Stock Holding History

Saxon Interests’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$592K	Buy	11,657 +5	+0%	+$233	0.2%	127
2025 Q4	$344K	Buy	+11,652	New	+$317K	0.12%	154

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Saxon Interests's MRNA Position: Q1 2026 in Review

Saxon Interests increased its Moderna (MRNA) stake by 0.04% in Q1 2026, buying an estimated $233 and bringing the position to 11,657 shares worth $592K. The position accounts for 0.2% of the portfolio, ranked #127.

Saxon Interests first reported a position in MRNA in Q4 2025 and has held it in 2 quarters since. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Saxon Interests held 11,657 shares of Moderna worth $592K as of Q1 2026.
Saxon Interests bought 5 Moderna shares in Q1 2026, an estimated $233.
Moderna made up 0.2% of Saxon Interests's portfolio in Q1 2026, its #127 holding.
Saxon Interests first reported a position in Moderna in Q4 2025 and has held it in 2 quarters since.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Saxon Interests's 13F filing for Q1 2026, filed 29 Apr 2026.